<code id='114A61B06F'></code><style id='114A61B06F'></style>
    • <acronym id='114A61B06F'></acronym>
      <center id='114A61B06F'><center id='114A61B06F'><tfoot id='114A61B06F'></tfoot></center><abbr id='114A61B06F'><dir id='114A61B06F'><tfoot id='114A61B06F'></tfoot><noframes id='114A61B06F'>

    • <optgroup id='114A61B06F'><strike id='114A61B06F'><sup id='114A61B06F'></sup></strike><code id='114A61B06F'></code></optgroup>
        1. <b id='114A61B06F'><label id='114A61B06F'><select id='114A61B06F'><dt id='114A61B06F'><span id='114A61B06F'></span></dt></select></label></b><u id='114A61B06F'></u>
          <i id='114A61B06F'><strike id='114A61B06F'><tt id='114A61B06F'><pre id='114A61B06F'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          explore

          author:leisure time    - browse:19228
          Courtesy Sanofi

          LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

          The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.   

          advertisement

          Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          hotspot